Drug intelligence / Profile preview

ULREA-PVS-NP

Development stage
Phase 1
Lead developer
Kyushu University
Modality
Nanoparticles → Drug Delivery Systems, Small Molecules
Administration
Intravenous
01

Overview

ULREA-PVS-NP is an intravenous nanoparticle formulation of pitavastatin encapsulated in poly(lactic-co-glycolic acid) (PLGA), developed by researchers at Kyushu University. This therapeutic candidate is designed to treat retinitis pigmentosa (RP), a rare inherited retinal degenerative disease characterized by progressive visual field loss. The formulation utilizes PLGA nanoparticles to deliver pitavastatin, an HMG-CoA reductase inhibitor, to target and suppress the activity of inflammatory monocytes and macrophages in the retina. By modulating these inflammatory pathways, ULREA-PVS-NP aims to prevent photoreceptor degeneration and slow the progression of vision loss. It is currently undergoing Phase 1 clinical evaluation to assess its safety, tolerability, and pharmacokinetics in patients with RP.

Other names
pitavastatin PLGA nanoparticlespitavastatin PLGA nano-particle
02

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on ULREA-PVS-NP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ULREA-PVS-NP.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call